Sign in

    Elias Lenard

    Senior Research Analyst at JPMorgan Chase & Co.

    Elias Nicholas Lenard is a Senior Research Analyst at JPMorgan Chase & Co., specializing in biotechnology and pharmaceutical sector research. He covers key companies such as Insmed Inc. and Mirum Pharmaceuticals, contributing industry insight and analysis to earnings calls, although publicly available records do not list definitive performance track records or third-party rankings. Lenard has advanced through the research ranks at JPMorgan, with tenure visible at least since 2022, though specifics regarding his start date or prior roles are undisclosed in available sources. His professional credentials and securities licenses, as well as any industry recognitions, are not publicly documented at this time.

    Elias Lenard's questions to Immunocore Holdings (IMCR) leadership

    Elias Lenard's questions to Immunocore Holdings (IMCR) leadership • Q2 2024

    Question

    Elias Lenard, on behalf of Jessica Fye at JPMorgan, inquired about the upcoming brenetafusp ovarian cancer data at ESMO, asking about patient numbers, the mono/combo split, success benchmarks, and progress in the platinum-sensitive setting.

    Answer

    David Berman, Head of R&D, said the ESMO dataset size will be similar to the ASCO melanoma data, primarily monotherapy but with more combinations. He noted existing chemotherapy benchmarks are low, with response rates under 10%. Mohammed Dar, an executive, added that the study now allows moving into earlier, platinum-sensitive lines to test combinations with therapies like bevacizumab and platinum doublets.

    Ask Fintool Equity Research AI

    Elias Lenard's questions to Immunocore Holdings (IMCR) leadership • Q2 2024

    Question

    Elias Lenard, on behalf of Jessica Fye at JPMorgan, inquired about the upcoming brenetafusp ovarian cancer data at ESMO, including patient numbers and success benchmarks, and asked about progress in the platinum-sensitive setting.

    Answer

    David Berman, Head of R&D, said the ESMO data set will be similar in size to the ASCO melanoma data, mostly monotherapy, with success benchmarked against poor chemotherapy outcomes (single-digit response rates). Mohammed Dar, an executive, added that the study is now moving into earlier, platinum-sensitive lines to test combinations with bevacizumab and platinum doublets.

    Ask Fintool Equity Research AI

    Elias Lenard's questions to Immunocore Holdings (IMCR) leadership • Q2 2024

    Question

    Asked about the upcoming ESMO data for brenetafusp in ovarian cancer (patient numbers, data points, success benchmarks) and the timeline for data from the platinum-sensitive setting.

    Answer

    The ESMO data will be similar in size to the ASCO melanoma data, mostly monotherapy, with benchmarks being low single-digit response rates. The study is now moving into earlier, platinum-sensitive lines to test combinations with bevacizumab and platinum chemotherapy.

    Ask Fintool Equity Research AI